Ensuring Point-of-Care Testing Reliability in Viet Nam: Operator Competence, Quality Assurance and Clinical Oversight

DIAGNOSTIC SAFETY & RISK MANAGEMENTMEASUREMENT, LEARNING & IMPROVEMENT

11/5/202624 min read

Ensuring Point-of-Care Testing Reliability in Viet Nam: Operator Competence, Quality Assurance and Clinical Oversight

Point-of-care testing (POCT) can provide clinically useful information within minutes, often at the bedside or during the same consultation. In an emergency department, a blood gas result may help clinicians assess a rapidly changing condition. In intensive care, bedside glucose measurements may support ongoing monitoring. At an outpatient clinic, an appropriately selected rapid diagnostic test may help guide the next step in patient care.

The advantages are considerable. By bringing testing closer to patients, POCT can shorten the time between specimen collection and result availability, improve access to selected examinations and support more timely clinical decisions. It can also reduce reliance on specimen transport and centralized laboratory workflows, particularly where repeated testing is necessary or healthcare services are geographically separated.

Yet a result that appears quickly is not necessarily one that can be trusted. A glucose meter may display a plausible number despite unsuitable specimen collection conditions. A rapid test may be performed correctly but interpreted beyond its intended use. An instrument may pass an electronic self-check while other aspects of analytical quality remain inadequately controlled. Even an accurate measurement can create risk if it is recorded under the wrong patient's name or never reaches the clinician responsible for care.

These concerns reflect a defining feature of decentralized testing. POCT does not remove the quality responsibilities associated with laboratory examinations. Instead, many of those responsibilities must be managed in clinical environments where testing is frequently performed by personnel whose primary duties involve patient care rather than laboratory medicine.

For healthcare organizations in Viet Nam, the challenge extends beyond purchasing reliable devices. It involves ensuring that examinations are appropriate for their intended use, operators are competent, analytical performance is monitored and results are correctly documented and communicated. Clear responsibilities for quality oversight must also be established, particularly when testing takes place outside the direct supervision of laboratory professionals.

International standards and recent laboratory medicine research provide useful guidance for addressing these challenges. Their application, however, must reflect the actual testing environment, the organization's responsibilities and the applicable Vietnamese legal and professional framework.

What Makes a Point-of-Care Result Reliable?

Point-of-care testing generally refers to laboratory examinations performed at or near the location where healthcare is delivered, rather than through the conventional workflow of a centralized medical laboratory. It may take place in hospital wards, emergency departments, intensive care units, operating rooms, outpatient facilities and other appropriate healthcare settings.

The technologies involved differ substantially. POCT may include handheld glucose meters, blood gas analyzers, selected cardiac biomarker platforms, coagulation testing devices and certain rapid tests for infectious diseases. Some systems provide quantitative measurements, while others produce qualitative results. Their analytical capabilities, specimen requirements and clinical applications cannot be treated as interchangeable.

A device that is convenient to operate is not necessarily suitable for every clinical purpose. Some POCT systems are intended primarily for monitoring, while others support diagnostic evaluation or decisions that may have significant consequences for patient care. The analytical performance required for one application may not be sufficient for another.

Reliability therefore begins with selecting an appropriate examination. The method must be suitable for its intended clinical use, the device must operate under acceptable conditions, and competent personnel must follow established procedures. The result must also be correctly associated with the patient and interpreted in the relevant clinical context.

Analytical accuracy is essential, but it is only one part of the process. A technically acceptable result may still be unsuitable for a particular decision if it is obtained using an inappropriate specimen, interpreted against an unsupported clinical decision threshold or recorded without information needed to understand its significance.

Differences between POCT and central laboratory measurements also require attention. Two systems may measure the same analyte but use different specimen types, analytical principles or calibration approaches. Their results should not automatically be assumed to be interchangeable, particularly near clinically important decision thresholds.

For example, many handheld glucose meters use whole-blood specimens while reporting plasma-equivalent glucose concentrations. Although this supports clinical comparability, method-specific limitations remain relevant. Similarly, cardiac biomarker platforms differ in analytical sensitivity, precision and the clinical decision limits appropriate to their intended use.

It would be equally misleading to assume that central laboratory testing is always analytically superior. Modern POCT systems can achieve performance comparable to central laboratory methods for certain measurements, and some technologies have demonstrated substantial improvements over earlier generations.

In a 2026 paper published in Clinical Chemistry and Laboratory Medicine, Mario Plebani examined POCT from the perspective of value-based laboratory medicine. The analysis emphasizes analytical performance specifications, clinical purpose and the importance of distinguishing examinations used for diagnosis from those primarily intended for monitoring. It also highlights the need to assess whether faster access to testing produces meaningful clinical value.

For healthcare organizations, the central question is not simply where testing occurs. It is whether the examination provides information that is sufficiently reliable for the clinical decisions it is expected to support.

Why Decentralized Testing Requires Different Quality Arrangements

Central laboratories generally operate within established systems for specimen management, analytical examination, quality control, result verification and reporting. Laboratory personnel work with defined procedures, technical supervision and structured quality management arrangements.

POCT distributes parts of this process across clinical services, sometimes involving numerous devices and operators working in different locations.

A hospital may have glucose meters in several wards, blood gas analyzers in critical care areas and rapid testing platforms in outpatient departments. Nurses, physicians and other appropriately authorized personnel may operate these systems across different shifts, while laboratory professionals provide technical advice or quality oversight from another location.

These arrangements can improve efficiency, but they introduce additional opportunities for variation. Some operators use a particular device frequently and remain familiar with its procedures. Others may perform the same examination only occasionally. Staff rotation, turnover and changes in workload can make it difficult to maintain consistent competence.

Environmental conditions may also differ from those of a central laboratory. Reagents can be exposed to unsuitable temperatures, equipment may be moved between locations, and essential materials may not always be available when testing is required.

Information management presents another challenge. Some POCT devices transmit results directly to laboratory information systems or electronic health records. Others require manual documentation or retain results locally until they are retrieved. A result may be available immediately to the person performing the examination but remain inaccessible to another clinician involved in the patient's care.

These vulnerabilities do not mean that decentralized testing is inherently unsafe. They indicate that a reliable POCT service requires quality arrangements suited to the environment in which testing actually occurs.

Simply extending central laboratory procedures to every clinical location may not be sufficient. Testing frequency, operator experience, clinical urgency, environmental conditions and access to technical support should influence how safeguards are designed.

The objective is to maintain dependable quality across different locations without introducing unnecessary complexity that makes safe procedures difficult to follow.

Clinical and Laboratory Oversight: Establishing Clear Accountability

One of the most important questions in POCT governance is who is responsible for the quality of examinations performed outside the central laboratory.

A clinical department may purchase and operate a device while the medical laboratory provides training, quality assurance and technical advice. Another healthcare organization may manage POCT directly through its laboratory service. Some settings operate without medical laboratory training, supervision or support.

These different arrangements require careful consideration. Regardless of the organizational model, responsibilities should not be left to informal assumptions.

ISO 15189:2022 incorporates additional requirements for POCT in its normative Annex A. The standard assigns ultimate responsibility to the healthcare organization's governing body for ensuring that appropriate processes exist to monitor the accuracy and quality of POCT performed within the organization.

For laboratory-supported POCT, the standard also addresses responsibilities between the medical laboratory and the locations where testing takes place. These include arrangements concerning equipment selection, personnel training, competence assessment, quality assurance and oversight of the examination process.

The implication is important. The person operating a device should not be expected to carry responsibility for the entire quality system.

Healthcare organizations need to establish who has authority to introduce a new POCT method, evaluate its performance, approve procedures and monitor continuing quality. Responsibilities for operator authorization, quality control, equipment maintenance, incidents, corrective actions and result documentation should also be clearly assigned.

Where the medical laboratory is responsible for POCT, appropriately qualified laboratory professionals have an essential role in scientific and analytical oversight. Clinical departments remain responsible for their assigned operational activities, while authorized healthcare professionals retain responsibility for clinical decisions within their professional scope.

In larger hospitals, a multidisciplinary POCT committee may help coordinate these functions. Laboratory medicine, nursing, relevant clinical departments, biomedical engineering, information technology and quality management may all contribute to effective oversight.

Smaller healthcare organizations may use a simpler structure with designated responsible personnel and documented arrangements. The governance model should reflect the number of testing locations, the complexity of examinations and the potential consequences of failure.

International accreditation guidance provides further insight.

The European co-operation for Accreditation published EA-4/20 G:2026 on April 21, 2026. The document provides guidance for assessing POCT services against EN ISO 15189:2022 when medical laboratories carry overall responsibility for the examinations.

It addresses governance, personnel competence, quality assurance, information management, service continuity and the risks associated with testing across multiple locations.

Within the European Accreditation framework, implementation is scheduled for April 2027, with a one-year transition period. The document is intended for accreditation bodies and relevant medical laboratories. It should not be presented as a legal requirement automatically applicable to every healthcare organization in Viet Nam.

Not all POCT services operate under the same laboratory-supported model. ISO/TS 22583:2024 provides requirements and recommendations for supervisors and operators where POCT is performed without medical laboratory training, supervision or support. Patient self-testing is excluded from its scope.

The distinction matters because the appropriate governance arrangements depend on how the service is organized. A setting without laboratory support still needs suitable competence, quality assurance and accountability, but its arrangements should be evaluated against the requirements relevant to that service model.

Operator Competence Goes Beyond Learning to Use a Device

Many POCT systems are designed to be straightforward to operate. Automated prompts, small specimen volumes and rapid result displays can make the testing process appear relatively simple.

However, knowing which buttons to press is only one part of performing a reliable examination.

Before testing, the operator may need to confirm patient identity, ensure that the examination is appropriate, collect a suitable specimen and verify that the device and reagents are ready for use. During the examination, the operator must recognize relevant instrument warnings, specimen problems and quality control failures. After testing, the result must be documented correctly, and unexpected findings or technical concerns must be managed according to established procedures.

Competence therefore involves practical skills as well as an understanding of the factors that can compromise a result.

An effective training program should reflect the actual examination rather than rely entirely on a generic demonstration of the device. Personnel need to understand the approved workflow, specimen requirements, analytical limitations, quality control procedures and appropriate responses when testing conditions are unsuitable.

Competence assessment is equally important. Attendance at a training session demonstrates participation, but it does not necessarily establish that an operator can perform an examination reliably.

Initial authorization should be based on appropriate evidence of competence. Reassessment should take place at intervals determined by the method's complexity, the potential clinical consequences of error, organizational procedures and applicable requirements.

Additional assessment may be necessary when equipment or procedures change, when an operator has not used a particular system for an extended period or when an incident raises concerns about performance.

Records should allow the organization to identify which personnel are authorized to perform particular examinations and whether their required competence assessments remain current.

Where supported by the technology, operator identification, electronic authorization and access controls can improve traceability and help prevent unauthorized testing. Their use should reflect the capabilities of the device and the risks associated with the examination.

Competence also depends on the conditions in which personnel work. A well-trained operator may struggle to follow the correct procedure when instructions are unclear, devices are poorly maintained or essential supplies are unavailable.

Repeated errors should therefore prompt examination of both individual competence and the wider testing system. Additional training may be appropriate, but it will not resolve problems caused by unreliable equipment, unsuitable workflows or inadequate organizational support.

Selecting POCT Methods That Are Fit for Their Intended Use

Introducing a new POCT device should begin with the clinical need it is expected to address.

Faster result availability can be particularly valuable when delays influence time-sensitive decisions. However, speed alone does not establish that an examination will improve care. A rapid result may contribute little if the method is unsuitable, its limitations are poorly understood or the information is not integrated into an appropriate clinical pathway.

Before implementing a device, healthcare organizations should determine what clinical purpose the examination will serve and whether the selected technology can provide the necessary analytical performance.

Relevant considerations include accuracy, precision, measuring interval, analytical interferences, specimen requirements, clinical decision limits and environmental operating conditions. For qualitative examinations, diagnostic sensitivity, specificity and the circumstances in which additional testing may be needed can be particularly important.

The manufacturer's stated intended use provides an essential starting point. The organization must also consider whether its planned clinical application falls within that intended use.

A device evaluated for one specimen type or patient population should not automatically be assumed suitable for another. Performance achieved under controlled conditions may differ when testing takes place under unsuitable environmental conditions or when specimen collection procedures are inconsistent.

Analytical performance should be appropriately verified or validated before clinical implementation where required by the applicable standard, regulatory framework or quality management system. The extent of evaluation should reflect the intended clinical use and the potential consequences of an incorrect result.

Comparability with central laboratory methods deserves particular attention. Differences in analytical principles, calibration, specimen matrices and measurement uncertainty may influence the interpretation of results.

A POCT result should not automatically be assessed using a central laboratory reference interval or clinical decision threshold unless that application is supported for the particular method.

When results from different systems disagree, the explanation may involve legitimate methodological differences, specimen characteristics, biological changes or analytical problems. A discrepancy alone does not establish that either instrument is defective.

The purpose of method evaluation is to determine whether the examination can reliably support its intended clinical application, rather than assume that every system measuring the same substance produces interchangeable information.

Internal Quality Control and External Quality Assessment

Quality control is fundamental to POCT reliability, but decentralized testing requires arrangements that are appropriate to the device, analytical method and operating environment.

Internal quality control (IQC) provides information about whether the analytical system is functioning within established limits under defined conditions. It can help detect problems involving reagents, instruments, calibration or other factors affecting measurement reliability.

External quality assessment (EQA), including proficiency testing where appropriate, provides an additional means of evaluating performance through comparison with an external assessment scheme.

These activities have different purposes and should not be treated as interchangeable.

An instrument's electronic self-check may verify selected aspects of its functionality. It does not automatically establish that the analytical process is performing acceptably. Some POCT technologies incorporate manufacturer-designed internal checks or integrated quality assurance features, but their capabilities vary.

Healthcare organizations need to understand what those features assess, what they do not assess and which additional analytical controls are necessary.

The design and frequency of quality control should reflect the examination's intended use, manufacturer instructions, analytical performance, testing frequency and potential consequences of an unreliable result.

A uniform schedule applied to every POCT device without considering these factors may provide inadequate assurance in some circumstances while creating unnecessary operational burdens in others.

Plebani's 2026 analysis highlights persistent challenges in decentralized quality control, including variation in operator competence, limited testing volumes in some locations, difficulties obtaining suitable control materials and the absence of universally agreed POCT-specific quality control rules across all technologies.

These challenges do not make quality control optional. They reinforce the need for scientifically justified procedures that are suitable for the particular examination.

When a quality control result is unacceptable, the organization should have a defined response. Depending on the circumstances, this may involve suspending affected testing, examining reagents and equipment, investigating the cause, obtaining technical assistance and determining whether previously reported results could have been affected.

A failed analytical control should not be ignored because a patient urgently needs a result. Instead, the quality system should identify suitable alternatives for clinically necessary testing when the affected device cannot be used reliably.

External quality assessment provides another important source of information, although the suitability of available programs may differ between devices, specimen types and analytical methods.

For medical laboratories operating under applicable ISO 15189 requirements, appropriate EQA participation or suitable alternative approaches must be addressed according to the standard and the examination involved.

The EA-4/20 G:2026 guidance further describes risk-based EQA arrangements for POCT activities under medical laboratory responsibility. It calls for an EQA participation plan covering the relevant examination procedures and allows individual devices to be assessed within appropriately defined technical competence groups when equivalence is demonstrated through internal quality control, correlation studies and risk analysis.

This means that participation in EQA does not necessarily require every individual POCT device to be assessed separately. However, any grouping must be scientifically justified and meet the applicable accreditation requirements.

Where an appropriate EQA program is unavailable, other scientifically justified methods for assessing performance may be considered in accordance with the relevant standards and organizational obligations.

A satisfactory EQA result does not prove that every operator, device or testing location performs reliably on every occasion. Conversely, an unsatisfactory result requires investigation before its cause and clinical significance can be determined.

A dependable quality assurance system brings together internal controls, external assessment, equipment maintenance, competence records, incident findings and ongoing professional oversight.

Equipment, Reagents and Operational Readiness

Reliable testing depends on more than the analytical capabilities of a device. Instruments and materials must remain suitable for use under the conditions in which examinations are performed.

Clinical environments can differ substantially from controlled laboratory settings. Temperature, humidity, available storage space and equipment handling may influence performance or affect the stability of reagents and test strips.

Reagents should be stored and handled according to applicable manufacturer instructions. Expiry dates, storage conditions and requirements after opening may all affect their suitability.

Equipment management may involve maintenance, calibration, technical checks, software updates and monitoring of instrument performance. Responsibilities for these activities should be clearly assigned.

In organizations with multiple devices, equipment identification, inventory records and documented maintenance arrangements can help ensure that technical problems are recognized and addressed.

Changes in reagent lots, software, equipment configuration or testing procedures may require additional assessment, depending on the system and relevant quality requirements.

Healthcare organizations should also consider what happens when testing becomes unavailable.

A blood gas analyzer that fails during a busy clinical shift may create delays if no alternative examination pathway has been identified. Depending on the clinical situation, the organization may need access to another appropriately controlled POCT device, central laboratory testing or another suitable service.

Contingency arrangements should reflect the urgency of the required information and the capabilities of available resources.

Operational readiness therefore includes maintaining both the reliability of routine testing and the ability to respond safely when equipment, materials or supporting systems become unavailable.

Managing Unexpected Results and Protecting Clinical Decisions

A POCT result may occasionally be difficult to reconcile with the patient's clinical presentation or other available information.

Such findings require appropriate consideration, but disagreement does not necessarily indicate an analytical error. The result may reflect a genuine change in the patient's condition, differences between specimen types, methodological variation, interference or a problem during testing.

Some capillary blood measurements, for example, may be affected by collection conditions or patient physiology. Depending on the device and intended use, impaired peripheral perfusion or altered hematocrit may influence measurement reliability.

When a result appears inconsistent with the clinical situation, the responsible professional may need to consider the method's known limitations, review relevant testing conditions and determine whether further assessment is necessary.

This may involve checking specimen collection, device status, quality control information and the circumstances in which the examination was performed.

Repeat testing or examination using another appropriate method may be required in selected situations. The decision should reflect the clinical consequences of a potentially incorrect result, the characteristics of the method and the available evidence.

It would be inappropriate to require every POCT result to be confirmed through a central laboratory before clinical use. Such a practice could undermine the purpose of rapid testing and create unnecessary delays.

Equally, a result should not be accepted without question when there are credible reasons to doubt its validity.

If a significant analytical error is confirmed, the organization may need to identify affected results, assess whether patient care was influenced and implement corrective action.

An instrument malfunction, an incorrect measurement, an operator error and a diagnostic error are related but distinct events. A technical problem does not automatically mean that an incorrect diagnosis occurred, while a device that appears to function normally does not exclude other failures in the testing process.

The purpose of review is to understand what happened, protect clinical decision-making and reduce the likelihood of recurrence.

Result Identification, Documentation and Information Management

A technically accurate POCT result can still create risk if it is documented incorrectly or cannot be reliably associated with the patient.

Some devices transmit results automatically to laboratory information systems or electronic health records. Others rely on manual entry, local storage or subsequent transfer. These arrangements create different vulnerabilities.

Manual documentation may introduce transcription errors, incorrect measurement units or mismatches between results and patient records. Incomplete electronic integration may prevent another clinician from accessing information that could be important for ongoing care.

A reliable reporting process should preserve the information needed to identify the patient, examination, result, relevant units and time of testing. Depending on the method, additional information concerning the specimen, device, operator or analytical limitations may be necessary.

POCT results should also be distinguishable from central laboratory results when differences in specimen type, method or interpretation are clinically relevant.

Digital connectivity can improve traceability and reduce certain documentation errors, but automated transmission does not guarantee accuracy. Incorrect patient selection, unsuitable data mappings or differences in measurement units may still cause problems.

Healthcare organizations should therefore evaluate information transfer and record integrity as part of the POCT quality system rather than treating connectivity as a purely technical matter.

Clinically significant findings may also require timely communication according to the organization's established procedures. The presence of a result in an electronic record does not necessarily establish that the responsible clinician has reviewed it.

The responsibilities for producing a valid examination result, communicating urgent findings and making clinical decisions should be coordinated while remaining appropriately distinguished.

Risk Management and Measuring POCT Reliability

Risk management helps healthcare organizations determine which safeguards are necessary for a particular POCT service.

The risks associated with a frequently used glucose meter in a hospital ward may differ from those associated with a blood gas analyzer in intensive care or a rapid diagnostic platform in an outpatient facility.

Clinical consequences, testing frequency, operator competence, environmental conditions and the availability of alternative examinations should influence how risks are evaluated and controlled.

ISO 22367:2026, Medical Laboratories: Application of Risk Management to Medical Laboratories, provides an updated international framework for this work.

Published in April 2026, the second edition replaces ISO 22367:2020. It describes processes for identifying, estimating, evaluating, controlling and monitoring risks associated with medical laboratory examinations and services.

Its scope includes laboratory-related pre-examination, examination and post-examination activities, including accurate transmission of examination results into electronic medical records.

An important boundary should be maintained. ISO 22367:2026 does not directly address risks arising from clinical treatment decisions made by healthcare providers after examination results have been issued.

For POCT, risk assessment may identify vulnerabilities involving unauthorized operators, inconsistent specimen collection, unsuitable reagent storage, quality control failures, equipment downtime or incomplete result documentation.

The organization can then determine which controls are appropriate and how their effectiveness should be monitored.

A risk assessment should remain connected to actual clinical operations. Its purpose is not simply to produce documentation, but to identify realistic failure scenarios and establish practical measures that reduce the likelihood or consequences of harm.

Performance measurement provides evidence about whether those measures are working.

Turnaround time is an important indicator, but it does not fully describe POCT quality. A device may produce results rapidly while operator competence is poorly maintained, quality control is inconsistent or results are not reliably documented.

Healthcare organizations may therefore monitor the proportion of active operators with current authorization and competence assessment, adherence to established quality control procedures, equipment failures, maintenance compliance, corrective action completion and relevant quality incidents.

Information management indicators may examine whether results are correctly identified, recorded and transferred to the appropriate clinical information systems.

The selection of indicators should reflect the examination, testing environment and potential clinical consequences of failure. Not every device or department requires identical measures or targets.

Definitions and denominators deserve attention. An operator competence rate calculated only among personnel who attended training may overlook other staff who continue to perform examinations. A result-transfer success rate based only on connected devices may conceal weaknesses in departments that depend on manual documentation.

Organizations should also distinguish process performance from clinical benefit.

High compliance with training requirements does not establish that every examination is performed correctly. Successful electronic transmission does not prove that every result was appropriately interpreted. Similarly, shorter turnaround time does not necessarily produce faster clinical decisions or better patient outcomes.

Where feasible, evaluation should consider whether POCT contributes meaningfully to the clinical pathway for which it was introduced while maintaining dependable analytical quality.

Strengthening POCT Quality Within Viet Nam's Healthcare System

The implementation of POCT in Viet Nam must reflect the applicable legal framework, authorized professional activities and operating conditions of individual healthcare organizations.

Hospitals, outpatient facilities and other authorized healthcare settings may have different staffing arrangements, laboratory capabilities, information systems and access to technical expertise. An identical operational model should not automatically be imposed on every service.

The Law on Medical Examination and Treatment No. 15/2023/QH15, as amended and reflected in Consolidated Document No. 26/VBHN-VPQH dated February 26, 2026, provides the broader legal framework governing medical examination and treatment activities.

Decree No. 96/2023/ND-CP and relevant implementing provisions are also important when considering healthcare facility licensing, authorized technical activities and professional responsibilities.

POCT activities should be consistent with the healthcare organization's applicable licensing arrangements, the authorized scope of participating professionals and relevant technical requirements.

For laboratory quality management, Circular No. 01/2013/TT-BYT remains an important regulatory reference for medical examination and treatment facilities with laboratories.

The circular addresses laboratory quality management, organizational responsibilities, documented procedures, internal quality control, external quality assessment and quality improvement.

Article 7 concerns the responsibilities of healthcare facility leadership where a laboratory is present, while Article 10 addresses relevant responsibilities of clinical departments. These provisions reinforce the importance of coordination between laboratory and clinical services.

Circular No. 25/2026/TT-BYT, issued on June 30, 2026, amended Clause 5 of Article 5 of Circular No. 01/2013/TT-BYT. The amendment took effect on August 15, 2026.

The revised provision encourages healthcare facilities to participate in external quality assessment programs according to professional specialties, the Ministry of Health's arrangements for laboratory quality assurance responsibilities and recognized international EQA programs.

This provision should not be interpreted as imposing a universal obligation on every healthcare facility to participate in every available international EQA scheme. Other requirements concerning quality assurance may nevertheless arise from applicable legislation, the examination involved, accreditation arrangements or the organization's quality management commitments.

Decision No. 2429/QD-BYT, dated June 12, 2017, provides criteria for evaluating medical laboratory quality levels. It remains a relevant reference when considering laboratory quality improvement, although its original implementation arrangements and the applicability of particular provisions should be assessed in their proper regulatory context.

These documents are relevant to laboratory-supported POCT quality management. However, their application to an individual testing activity depends on the organizational arrangements, authorized technical scope and applicable legal requirements. They should not be described as establishing identical obligations for every decentralized testing device.

International standards provide an additional technical framework.

ISO 15189:2022 incorporates POCT requirements within Annex A, replacing the former separate ISO 22870:2016 framework.

Viet Nam's national standard, TCVN ISO 15189:2025, is identical to ISO 15189:2022 and replaces TCVN ISO 15189:2014. The standard may also be applied to POCT, making it relevant to medical laboratories and appropriate laboratory-supported POCT services developing their quality management arrangements.

However, the publication of TCVN ISO 15189:2025 does not mean that every POCT device or service in Viet Nam must obtain separate ISO 15189 accreditation.

Under the European Accreditation guidance, ISO 15189 accreditation of POCT is organized through medical laboratories that maintain overall technical and organizational responsibility for the examinations. This specific accreditation arrangement should not be confused with a general legal requirement for all healthcare organizations operating POCT devices.

Whether particular requirements are mandatory in Viet Nam depends on the applicable legal provisions, licensing conditions, contractual obligations and relevant accreditation scope.

Medical device regulation is another important consideration.

Decree No. 98/2021/ND-CP on medical device management, as amended and reflected in Consolidated Document No. 08/VBHN-BYT dated March 6, 2026, provides a framework for managing medical devices.

Circular No. 24/2026/TT-BYT, effective July 1, 2026, addresses the determination of medical device product risk levels and corresponding management measures, while amending certain implementing provisions.

Healthcare organizations should consider the regulatory status, intended use and relevant requirements of POCT devices and associated in vitro diagnostic products when procuring and operating them.

Nevertheless, a device's compliance with applicable product regulations does not establish that every clinical service using it has adequately trained operators, suitable analytical quality control or reliable result-management procedures.

Device compliance and service quality assurance are related but distinct responsibilities.

Patient information protection also requires attention, particularly as POCT systems become increasingly connected.

Viet Nam's Law on Personal Data Protection No. 91/2025/QH15 and its implementing Decree No. 356/2025/ND-CP took effect on January 1, 2026.

POCT systems may process identifiable patient information, examination results, operator records and device-related data. Depending on their configuration, they may also transmit information to external software platforms or cloud-based services.

Healthcare organizations should evaluate the applicable requirements concerning lawful data processing, confidentiality, access control, information security, disclosure and domestic or international data transfers.

Consent requirements, applicable exceptions and other relevant legal conditions need to be considered according to the purpose and circumstances of the processing activity.

Where external technology providers have access to clinical information, the organization should understand how data are processed, where they are transmitted, which parties may access them and how responsibilities are allocated.

For POCT services, analytical reliability, clinical accountability and patient information protection should be treated as connected aspects of safe healthcare delivery.

Building a Practical POCT Quality Improvement Program

Improving POCT reliability does not necessarily require a healthcare organization to replace its devices or introduce a large accreditation project.

A useful starting point is to understand how testing is currently performed.

The organization can identify which examinations are available, where devices are located, who operates them, what clinical purposes they serve and which quality arrangements are already in place.

This review may reveal significant differences between departments. One clinical unit may maintain complete operator authorization and quality control records, while another uses similar equipment without a consistent process for assessing competence. Some devices may transmit results automatically, while others depend on manual documentation.

The organization should then prioritize improvement according to clinical risk and the reliability of existing controls.

An examination that directly influences urgent decisions may require particular attention to analytical performance, operator competence and contingency arrangements. Another service may have lower immediate clinical risk but substantial weaknesses in data traceability or equipment management.

Improvement priorities should be based on local evidence rather than assumptions about which devices are most advanced or which departments perform the greatest number of examinations.

A focused initiative could begin with one POCT examination in a selected clinical department.

The responsible team can review the intended clinical application, operating procedures, staff competence, quality control arrangements, equipment management and result documentation. It should also examine what happens when a result appears unreliable, a quality control check fails or a device becomes unavailable.

Baseline performance can then be assessed using a manageable number of indicators.

After introducing changes, the organization should review whether testing reliability has improved and whether the intervention has created new operational difficulties.

For example, electronic patient identification may reduce certain manual errors but create delays if connectivity is unreliable. A revised quality control process may strengthen analytical assurance while requiring additional attention to staffing and material availability.

Such consequences should be considered when refining the intervention.

Personnel involved in actual testing should participate in improvement activities. Nurses, physicians, laboratory professionals, biomedical engineering personnel, information technology staff and quality managers may each recognize different weaknesses in the workflow.

Their involvement can help ensure that procedures are technically appropriate and practical enough to be followed consistently during routine clinical care.

A sustainable POCT quality program also requires periodic review of device performance, competence records, quality control findings, incidents and the continuing clinical suitability of the service.

The objective is not to create more policies or training certificates. It is to establish a dependable testing process in which important risks are recognized, responsibilities are clear and quality safeguards remain effective under actual operating conditions.

From Rapid Results to Reliable Diagnostic Care

Point-of-care testing offers important opportunities to improve access to diagnostic information and support timely patient care. Its value is particularly apparent when testing can be brought closer to patients without compromising the analytical quality needed for the intended clinical decision.

Achieving that balance requires more than reliable equipment. Competent operators, appropriate method selection, quality assurance, equipment readiness and accurate result documentation must work together within a clearly governed service. The medical laboratory, clinical departments and healthcare organization each have responsibilities that need to be understood and coordinated according to the actual operating model.

International standards, including ISO 15189:2022, ISO/TS 22583:2024 and ISO 22367:2026, provide relevant frameworks for strengthening these arrangements. The 2026 European Accreditation guidance and recent laboratory medicine research offer further insight into managing the distinctive risks of decentralized testing.

For healthcare organizations in Viet Nam, the priority is to apply these principles in ways that are consistent with applicable legal requirements and achievable within their clinical settings.

Reliable POCT is not demonstrated simply by obtaining a result within minutes. It depends on whether the organization can explain why the result is trustworthy, recognize when it may not be reliable and ensure that the appropriate professionals can act on the information safely.

The contribution of point-of-care testing to diagnostic excellence ultimately depends on combining timely access to results with dependable quality, clear accountability and appropriate clinical use.

Selected References and Regulatory Sources

International Organization for Standardization. ISO 15189:2022. Medical Laboratories: Requirements for Quality and Competence. Annex A: Additional Requirements for Point-of-Care Testing.

International Organization for Standardization. ISO 22367:2026. Medical Laboratories: Application of Risk Management to Medical Laboratories. Second edition, April 2026.

International Organization for Standardization. ISO/TS 22583:2024. Requirements and Recommendations for Supervisors and Operators of Point-of-Care Testing (POCT) Equipment. Second edition, September 2024.

International Organization for Standardization. ISO 22870:2016. Point-of-Care Testing (POCT): Requirements for Quality and Competence. Withdrawn and replaced by ISO 15189:2022.

European co-operation for Accreditation. EA-4/20 G:2026. Guidance for the Assessment of Laboratories Against EN ISO 15189:2022: Point-of-Care Testing (POCT). Published April 21, 2026. Implementation scheduled for April 2027, with a one-year transition period.

Plebani M. Point-of-care testing in the era of value-based laboratory medicine. Clinical Chemistry and Laboratory Medicine. 2026;64(7):1489–1499. DOI: 10.1515/cclm-2026-0309.

Viet Nam National Standard. TCVN ISO 15189:2025. Medical Laboratories: Requirements for Quality and Competence. Identical to ISO 15189:2022 and replacing TCVN ISO 15189:2014.

National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15, as amended and reflected in Consolidated Document No. 26/VBHN-VPQH dated February 26, 2026.

Government of Viet Nam. Decree No. 96/2023/ND-CP, detailing certain provisions of the Law on Medical Examination and Treatment, as amended where applicable.

Ministry of Health of Viet Nam. Circular No. 01/2013/TT-BYT, guiding the implementation of laboratory quality management at medical examination and treatment facilities, as subsequently amended.

Ministry of Health of Viet Nam. Circular No. 25/2026/TT-BYT, amending and supplementing provisions of Circular No. 01/2013/TT-BYT and other Ministry of Health circulars. Issued June 30, 2026. The amendment to Circular No. 01/2013/TT-BYT took effect on August 15, 2026.

Ministry of Health of Viet Nam. Decision No. 2429/QD-BYT, promulgating criteria for assessing the quality levels of medical laboratories. June 12, 2017.

Government of Viet Nam. Decree No. 98/2021/ND-CP on Medical Device Management, as amended and reflected in Consolidated Document No. 08/VBHN-BYT dated March 6, 2026.

Ministry of Health of Viet Nam. Circular No. 24/2026/TT-BYT, concerning the determination of medical device product risk levels, corresponding management measures and amendments to relevant implementing provisions. Effective July 1, 2026.

National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. Effective January 1, 2026.

Government of Viet Nam. Decree No. 356/2025/ND-CP, detailing certain provisions and implementation measures of the Law on Personal Data Protection. Effective January 1, 2026.

Professional Scope and Disclaimer

This article is published by Diagnostic Excellence Vietnam (DxEx.vn), a professional initiative dedicated to advancing diagnostic quality, safety and reliability in Viet Nam through evidence-informed knowledge sharing, risk management, measurement and quality improvement.

The content is intended for general professional education and discussion. It does not constitute patient-specific medical advice, a clinical or laboratory diagnosis, an individualized recommendation concerning the selection, operation or interpretation of point-of-care tests, a determination of professional or technical error, an accreditation assessment or legal advice.

References to international standards, professional guidance and accreditation documents do not imply that they are automatically mandatory under Vietnamese law. Their applicability depends on the relevant legal, organizational, contractual and accreditation arrangements.

Decisions concerning POCT implementation, operator authorization, analytical quality, examination procedures, result reporting, clinical interpretation and patient management must be undertaken by appropriately qualified and authorized professionals in accordance with applicable Vietnamese law, relevant professional standards, the manufacturer's intended use, appropriately verified or validated procedures and the patient's clinical circumstances.

Diagnostic Excellence Vietnam does not provide clinical diagnosis or treatment services.